Search the Newsreel

Prothena Q2 Results: Financial data release set for Aug 6

Prothena Corporation plc is scheduled to release its Q2 and H1 2026 financial results on Thursday, August 6, 2026, after the close of U.S. financial markets. The biotech company, which specializes in protein dysregulation therapies for neurodegenerative diseases, will not hold a conference call …

Form 4 PROTHENA CORP PUBLIC LTD CO For: 30 July By Investing.com

This article reports on the filing of Form 4 for Prothena Corp Public Ltd Co on July 30, as published by Investing.com. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change …

All eyes on Proto Labs earnings amid drone, data center surge

Proto Labs Inc. is set to announce its second-quarter earnings, with investors looking to see if the digital manufacturer can maintain its strong growth, especially in high-growth sectors like drones and data centers. Analysts anticipate earnings of $0.53 per share on revenue of $144.5 …

PRTA|Prothena Corporation PLC|Price:8.090|Chg%:-0.320

This article provides a detailed financial overview and market analysis of Prothena Corporation PLC (PRTA). It highlights the company's strong fundamentals, high growth potential, and current valuation as fairly valued within the Biotechnology & Medical Research industry. The report also includes key insights such …

Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Protagonist Therapeutics Inc (PTGX), noting its current valuation score of 4.19, which ranks it low within the Biotechnology & Medical Research industry. The company's P/E ratio is reported at -75.74, showing significant fluctuations from its recent high …

Sprott Inc. Q2 Results: Webcast scheduled for August 5

Sprott Inc., an asset manager specializing in precious metals and critical materials, will release its second-quarter 2026 financial results on August 5, 2026, at 7:00 a.m. ET. Following the release, the company will host an earnings webcast at 10:00 a.m. ET, led by CEO …

Proto Labs (PRLB) Reports Earnings Tomorrow: What To Expect

Proto Labs (PRLB) Reports Earnings Tomorrow: What To Expect Manufacturing services provider Proto Labs (NYSE:PRLB) will be reporting results this Friday before the bell. Here's what to expect. Proto Labs beat analysts' revenue expectations last quarter, reporting revenues of $139.3 million, up 10.4% year …

Sprott Inc. Revenue Breakdown – HAM:A781

Sprott Inc. (HAM:A781) generated €242.72 million in revenue last year, with its top-performing segment, Exchange Listed Products, contributing €97.85 million. The largest portion of revenue, €137.88 million, came from Canada. This data provides a financial overview of the company's performance by segment and geographical …

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Stempoint Capital LP

Stempoint Capital LP has increased its holdings in Protagonist Therapeutics (NASDAQ:PTGX) by 22.1%, acquiring an additional 13,147 shares to own a total of 72,577 shares valued at $7.65 million. This makes Protagonist Therapeutics the 26th largest holding for Stempoint Capital, comprising about 1.5% of …

Protara Therapeutics Inc (TARA) Valuation: PE, PB & Fair Value Analysis

Protara Therapeutics Inc (TARA) has a current valuation score of 6.67, placing it 292nd out of 384 in the Biotechnology & Medical Research industry. Its P/E ratio is -2.97. However, key P/B and P/CF data have not yet been disclosed by the company.

Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis

Prothena Corporation PLC (PRTA) has a robust financial score of 9.21, ranking 10th in the Biotechnology & Medical Research industry. The company demonstrated high operating efficiency with a 1706.36% year-over-year revenue increase and a 154.36% net profit increase in its latest quarter. Its financial …

Avoiding Lag: Real-Time Signals in (FUND) Movement

This article from Stock Traders Daily discusses real-time trading signals for Sprott Focus Trust Inc. (NASDAQ: FUND), highlighting a neutral near and mid-term outlook but a long-term positive bias. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with …

Protara Therapeutics Inc (TARA) Financial Health: Profitability & Balance Sheet Analysis

Protara Therapeutics Inc (TARA) has a robust financial status with a current financial score of 7.14, ranking 147 out of 384 in the Biotechnology & Medical Research industry, though its operating efficiency is low. The article provides an overview of various financial indicators, including …

Pre-registration opens for Sprott's Aug. 5 results webcast

Prothena Sets Aug. 6 Results Release, No Conference Call

Sprott Physical Copper Trust Updates Its 'At-The-Market” Equity Program

Sprott Physical Copper Trust has updated its "at-the-market" (ATM) equity program, allowing it to issue up to U.S.$250 million in Units in Canada and the United States. This new ATM program replaces a previous one announced in May 2026. The Trust intends to use …

BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Prothena Corporation plc common stock. This translates to 3,587,480 shares, with BlackRock holding sole voting power over 3,533,090 shares and sole dispositive power over all 3,587,480 shares. The filing …

Proto Labs, Inc. Revenue Breakdown – MUN:PRZ

This article provides a revenue breakdown for Proto Labs, Inc. (MUN:PRZ), detailing its top-performing segment and geographical contributions. In the last year, the company generated €453.91 million in revenue, with Computer Numerical Control Machining being the leading segment and the United States contributing the …

Sprott (SII) Expected to Announce Quarterly Earnings on Wednesday

Sprott (NYSE:SII) is scheduled to release its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts anticipate earnings of $1.31 per share on revenue of $82.45 million. The company previously exceeded estimates in Q1 2026 with $1.13 EPS and $80.75 million in …

Proto Labs Inc (PRLB) Financial Health: Profitability & Balance Sheet Analysis

Proto Labs Inc (PRLB) currently has a strong financial score of 8.33, ranking 22nd in its industry, indicating robust financial status and high operating efficiency. The company recently reported a quarterly revenue of $139.34M, marking a 10.40% year-over-year increase, and a significant 125.37% increase …

Protagonist Therapeutics (PTGX) Projected to Post Earnings on Wednesday

Protagonist Therapeutics Inc (PTGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Protagonist Therapeutics Inc (PTGX), focusing on its price momentum, support and resistance levels, and key indicators like MACD, RSI, and moving averages. As of July 28, 2026, PTGX had a price momentum score of 4.02 and was …

Sprott Inc. (SII) discloses $3.15B across 268 positions in latest 13F

Sprott Inc. has filed a quarterly Form 13F Holdings Report, disclosing $3.15 billion across 268 reportable equity and related positions. The report indicates that Sprott Inc. is the sole institutional investment manager reporting these holdings, with no other managers included. This filing provides insight …

Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.29 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.05, comparing it to recent highs and lows. The analysis also states …

Rubric Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX

Rubric Capital Management LP has acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), purchasing 427,998 shares valued at approximately $45.1 million, which represents 0.67% of the company. Institutional investors now own 98.63% of PTGX, despite recent insider selling by the CEO and a …

Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV

This article provides a revenue breakdown for Prothena Corp. Plc (LSX:A1KAVV). Last year, the company generated 8.25 million EUR, predominantly from its "Collaboration" segment, which contributed 8.20 million EUR. The revenue was primarily sourced from the United States.

Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Prothena Corporation PLC (PRTA), identifying its major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters, showing changes in shares held and proportion, and lists …

Rubric Capital Management LP Has $48.60 Million Position in Prothena Corporation plc $PRTA

Protagonist Therapeutics, Inc. $PTGX Stock Position Lifted by Eagle Health Investments LP

Prothena Corporation PLC (PRTA) Cash Flow

This article provides a comprehensive overview of Prothena Corporation PLC's (PRTA) cash flow statement, including detailed quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering insight into the company's financial health and stability. The …

PRTA|Prothena Corporation PLC|Price:8.700|Chg%:-0.050

This article provides a detailed financial summary of Prothena Corporation PLC (PRTA), including its latest earnings report, income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS

Protagonist Therapeutics Inc

This article from TradingKey provides a company overview for Protagonist Therapeutics Inc (PTGX), focusing on its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article primarily displays …

Short Interest in Sprott Focus Trust, Inc. (NASDAQ:FUND) Expands By 210.4%

Short interest in Sprott Focus Trust, Inc. (NASDAQ:FUND) surged by 210.4% in July, reaching 38,704 shares, though this still represents only 0.3% of shares sold short and a short-interest ratio of 0.7 days. The company recently increased its quarterly dividend to $0.1424 per share, …

TARA|Protara Therapeutics Inc|Price:3.938|Chg%:-0.102

This article provides a comprehensive stock analysis of Protara Therapeutics Inc (TARA) from TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and multiple Buy ratings …

Protara Therapeutics Inc (TARA) Institutional Confidence

Protara Therapeutics Inc (TARA) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 85.08%, which is a 61.63% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.26 million shares.

Sprott Inc (SII) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts for Sprott Inc (SII), detailing dividend amounts, record dates, payment dates, and ex-dividend dates from February 2024 through May 2026. It highlights that Sprott Inc has distributed a total of 104.34M USD in dividends over …